Novo Nordisk A/S (NVO)
NYSE: NVO · IEX Real-Time Price · USD
126.85
+1.06 (0.84%)
At close: Apr 26, 2024, 4:00 PM
127.30
+0.45 (0.35%)
After-hours: Apr 26, 2024, 7:59 PM EDT
Novo Nordisk Revenue
In the year 2023, Novo Nordisk had annual revenue of 232.26B DKK with 31.26% growth. Revenue in the quarter ending December 31, 2023 was 65.86B DKK with 36.95% year-over-year growth.
Revenue (ttm)
232.26B DKK
Revenue Growth
+31.26%
P/S Ratio
16.51
Revenue / Employee
3,611,079 DKK
Employees
64,319
Market Cap
550.22B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
Dec 31, 2009 | 51.08B | 5.41B | 11.85% |
Dec 31, 2008 | 45.67B | 3.78B | 9.02% |
Dec 31, 2007 | 41.89B | 3.14B | 8.10% |
Dec 31, 2006 | 38.75B | 5.04B | 14.94% |
Dec 31, 2005 | 33.71B | 4.48B | 15.33% |
Dec 31, 2004 | 29.23B | 2.62B | 9.85% |
Dec 31, 2003 | 26.61B | 1.46B | 5.80% |
Dec 31, 2002 | 25.15B | 1.44B | 6.06% |
Dec 31, 2001 | 23.72B | 2.90B | 13.94% |
Dec 31, 2000 | 20.82B | -129.38M | -0.62% |
Dec 31, 1999 | 20.94B | 3.03B | 16.94% |
Dec 31, 1998 | 17.91B | 925.65M | 5.45% |
Dec 31, 1997 | 16.98B | 2.08B | 13.96% |
Dec 31, 1996 | 14.90B | 1.19B | 8.68% |
Dec 31, 1995 | 13.71B | 195.28M | 1.44% |
Dec 31, 1994 | 13.52B | 372.23M | 2.83% |
Dec 31, 1993 | 13.15B | 2.47B | 23.19% |
Dec 31, 1992 | 10.67B | 841.36M | 8.56% |
Dec 31, 1991 | 9.83B | 1.50B | 17.97% |
Dec 31, 1990 | 8.33B | 712.77M | 9.36% |
Dec 31, 1989 | 7.62B | 1.99B | 35.34% |
Dec 31, 1988 | 5.63B | 602.02M | 11.97% |
Dec 31, 1987 | 5.03B | 840.36M | 20.07% |
Dec 31, 1986 | 4.19B | 29.03M | 0.70% |
Dec 31, 1985 | 4.16B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
NVO News
- 3 days ago - Senate launches investigation into high prices of Ozempic and Wegovy in the U.S. - CNBC
- 3 days ago - US Senate committee investigates pricing of Novo's Ozempic and Wegovy - Reuters
- 3 days ago - Novo Nordisk A/S - Articles of Association, April 2024 - GlobeNewsWire
- 3 days ago - Novo Nordisk A/S – Reduction of the share capital - GlobeNewsWire
- 5 days ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 9 days ago - Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500 - Market Watch
- 9 days ago - German watchdog approves Novo's acquisition of Cardior Pharmaceuticals - Reuters
- 11 days ago - Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates. - Market Watch